Tenax Therapeutics (NASDAQ:TENX) Now Covered by StockNews.com

StockNews.com assumed coverage on shares of Tenax Therapeutics (NASDAQ:TENXGet Rating) in a research report issued to clients and investors on Friday. The firm set a “sell” rating on the specialty pharmaceutical company’s stock.

Shares of TENX opened at $0.59 on Friday. Tenax Therapeutics has a 12-month low of $0.50 and a 12-month high of $2.30. The business’s fifty day moving average is $0.67 and its 200 day moving average is $0.90. The stock has a market cap of $14.77 million, a P/E ratio of -0.24 and a beta of 2.00.

A hedge fund recently raised its stake in Tenax Therapeutics stock. Morgan Stanley raised its stake in shares of Tenax Therapeutics, Inc. (NASDAQ:TENXGet Rating) by 1,932,400.0% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 38,650 shares of the specialty pharmaceutical company’s stock after acquiring an additional 38,648 shares during the period. Morgan Stanley owned about 0.15% of Tenax Therapeutics worth $80,000 as of its most recent SEC filing. 32.00% of the stock is currently owned by institutional investors and hedge funds.

About Tenax Therapeutics (Get Rating)

Tenax Therapeutics, Inc, a specialty pharmaceutical company, engages in identifying, developing, and commercializing products for cardiovascular and pulmonary diseases in the United States and Canada. It develops TNX-103 and TNX-102 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of pulmonary arterial hypertension.

See Also

Receive News & Ratings for Tenax Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tenax Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.